

Virtual regulatory assessment (VRA) and site visit audit report

VRA: 15 July 2021

Site visit: 24 August 2021



Cardiff and Vale University Health Board

HTA licensing number 40037

Licensed under the Human Tissue Quality and Safety of Organs Intended for Transplantation Regulations 2012 (as amended).

Licensed activities – Procurement

Organ type	Kidney	Liver	Pancreas
Adult (living donor)	DC, OC, P, T, R		
Adult (deceased donor)	OC, P, T, R	OC, P, T, R	OC, P, T, R

Procurement Activities: donor characterisation (DC), organ characterisation (OC), preservation of an organ (P), making arrangements to transport an organ (T), retrieval of an organ (R)

Licensed activities – Transplantation

Organ type	Kidney	Pancreas
Adult recipient	OC, P, T, I	OC, P, T, I
Paediatric recipient	OC, P, T, I	

Transplantation Activities: organ characterisation (OC), preservation of an organ (P), making arrangements to transport an organ (T), implantation of an organ (I)

Summary of audit findings

Cardiff and Vale Health Board (the establishment) was found to have met all HTA assessment criteria that were assessed as part of the VRA and site visit.

Background

The establishment has been licensed by the HTA since December 2012. This was the establishment's first VRA. Before that two site visit audits of the establishment have been conducted; the most recent previous audit took place in December 2016.

Since then, the establishment has initiated a normo-thermic regional perfusion (NRP) protocol during organ retrieval following staff training and evaluation in the new procedure.

In addition, the establishment has also started a Hepatitis C positive cadaveric donor transplant programme. All potential recipients are given an option to join this programme at the point of listing for transplantation, additional information regarding the programme is given to them to helpfully inform patients. Potential recipients can opt-in or out of the programme and their decision regarding this is re-visited annually while they are on the waiting list for transplantation.

Finally, the establishment has reconfigured its living kidney donor workup pathway. Changes have been made to the information provided to donors, donor visits and reviews of donors. The aim of the reconfiguration is to reduce both the amount of time spent at the hospital and the number of hospital visits required of potential living donors.

Description of VRA activities undertaken

The HTA's regulatory requirements are set out in Appendix 1 and 3. The following areas were covered during the VRA: discussion on the changes to the service, a review of five pre-selected incidents and staff training.

Review of governance documentation

Before the VRA, the following documents were reviewed: procedural documents relating to licensed activities, contracts for servicing of perfusion equipment and records of servicing, accreditation certificates for the Histocompatibility and Immunogenetics (H&I) and Microbiology laboratories, reported incidents and adverse events, the procurement policy demonstrating how the Medical Devices Regulations 2002 (SI 2002/618) (as amended) (UK MDR 2002) requirement is complied with and certification of the sterile services provider.

Site Visit inspection

A visit to the 'retrieval and storage' room on the renal ward was undertaken. This is where the cadaveric donor organs, received by the establishment, are stored and monitored prior to their transfer to theatres for implantation. The organ transport boxes, surgical retrieval kits, NRP equipment and perfusion fluids are also kept in this room.

Audit of records

A review of one set of living kidney donor notes was undertaken. This contained a copy of the Living Kidney Donor Pathway document which recorded the mandatory virology and other donor/organ characterisation tests, in addition to the Multi-Disciplinary Team discussions relating to the donors, the HTA authorisation and the HTA-A form.

A review of three sets of organ recipient clinical notes and the associated deceased organ donor files was also undertaken. Records of consent to being registered on the transplant list, copies of the HTA-A form, details of perfusion fluids used, consent to transplant, copies of the donor information on Electronic Offering System (EOS), the transplant co-ordinator notes, COVID - 19 questionnaire and the 'Kidney/Pancreas Received for Transplant' form were reviewed and were present in all three cases.

In all three cases, records of risk-benefit conversations relating to tissue type mismatches or risks of malignancy transmission were present within the notes, evidencing that the implanting surgeon had held the relevant discussions with the recipients before implantation.

The HTA-B forms are now in an electronic format and located on a secure computer. Due to limitations of COVID - 19 social distancing requirements, these records were not reviewed on this occasion.

No anomalies were identified during the VRA or the site visit.

Report sent for factual accuracy: 20 September 2021

Report returned with comments: 21 September 2021

Final report issued: 24 September 2021

Appendix 1: The HTA's regulatory requirements

The HTA shall ensure that licence holders are audited for the purposes of ensuring compliance with the licensing conditions in schedule 1 of The Quality and Safety of Organs Intended for Transplantation Regulations 2012 (as amended) and any requirements imposed by directions made under these Regulations.

The assessment criteria reflect the requirements of the statutory conditions outlined in schedule 1 and the HTA's directions. They are designed to promote the safe use of human organs and ensure traceability is maintained between donor and recipient. The HTA audits establishments it licences against eight groups of assessment criteria:

- Donor characterisation and organ characterisation
- Retrieval of organs for transplantation
- Organ preservation
- Making arrangements to transport an organ
- Implantation
- Traceability
- Serious adverse events and serious adverse reactions
- General (apply to all licences)

Reports of HTA audits are published on the HTA's website.

Throughout the audit process, the HTA assesses the establishment against the assessment criteria. Where the HTA determines that an assessment criterion is not met, the level of the shortfall is classified as 'Critical', 'Major' or 'Minor' (see Appendix 2: Classification of the level of shortfall). Where HTA assessment criteria are fully met, but the HTA has identified an area of practice that could be further improved, advice is provided in this report.

Appendix 2: Classification of the level of shortfall

Where the HTA determines that an assessment criterion is not met, the improvements required will be stated and the level of the shortfall will be classified as 'Critical', 'Major' or 'Minor'. Where the HTA is not presented with evidence that an establishment meets the requirements of an assessment criterion, it works on the premise that a lack of evidence indicates a shortfall.

The action an establishment will be required to make following the identification of a shortfall is based on the HTA's assessment of the risk of harm and/or a breach of the HT Act or associated Directions.

1. Critical shortfall:

A shortfall which poses a significant direct risk of causing harm to the quality of an organ intended for transplantation or which poses a significant direct risk of causing harm to a donor or recipient.

or

A number of 'major' shortfalls, none of which is critical on its own, but viewed cumulatively represent a systemic failure and therefore are considered 'critical'.

A critical shortfall may result in one or more of the following:

- (1) A notice of proposal being issued to revoke the licence
- (2) Some or all of the licensable activity at the establishment ceasing with immediate effect until a corrective action plan is developed, agreed by the HTA and implemented.
- (3) A notice of suspension of licensable activities
- (4) Additional conditions being proposed
- (5) Directions being issued requiring specific action to be taken straightaway

2. Major shortfall:

A non-critical shortfall; a shortfall in the carrying out of licensable activities which poses an indirect risk to the quality and safety of an organ intended for transplantation or which poses an indirect risk to the safety of a donor or recipient

or

A shortfall in the establishment's quality and safety procedures which poses an indirect risk to the quality and safety of an organ intended for transplantation or which poses an indirect risk to the safety of a donor or recipient;

or

A shortfall which indicates a major deviation from the **Human Tissue (The Quality and Safety of Organs Intended for Transplantation) Regulations 2012 (as amended)** or the **Documentary Framework for the Quality and Safety of Organs Intended for Transplantation**;

or

A combination of several 'minor' shortfalls, none of which is major on its own, but which, viewed cumulatively, could constitute a major shortfall by adversely affecting quality and safety of an organ intended for transplantation or the safety of a donor or recipient;

In response to a major shortfall, an establishment is expected to implement corrective and preventative actions within 1-2 months of the issue of the final audit report. Major shortfalls pose a higher level of risk and therefore a shorter deadline is given, compared to minor shortfalls, to ensure the level of risk is reduced in an appropriate timeframe.

3. Minor shortfall:

A shortfall which cannot be classified as either critical or major and, which can be addressed by further development by the establishment.

This category of shortfall requires the development of a corrective action plan, the results of which will usually be assessed by the HTA either by desk-based review or at the time of the next audit.

In response to a minor shortfall, an establishment is expected to implement corrective and preventative actions within 3-4 months of the issue of the final audit report.

Follow up actions

A template corrective and preventative action plan will be sent as a separate Word document with the final audit report. The establishment must complete this template and return it to the HTA within 14 days of the issue of the final report.

Based on the level of the shortfall, the HTA will consider the most suitable type of follow-up of the completion of the corrective and preventative action plan. This may include a combination of:

- a follow-up site-visit audit
- a request for information that shows completion of actions
- monitoring of the action plan completion
- follow up at next routine site-visit audit

After an assessment of the proposed action plan, the establishment will be notified of the follow-up approach the HTA will take.

Appendix 3: HTA Assessment criteria

The HTA assessment criteria applicable to this establishment are shown below; those not assessed during the VRA are shown in grey text. Individual standards which are not applicable to this establishment have been excluded.

Donor Characterisation and Organ Characterisation

CT1) Where a donor is deceased, a registered medical practitioner, or a person acting under the supervision of a registered medical practitioner, has endeavored to obtain information from the relatives or other persons about the donor, and has explained the importance of swift transmission of information.

(The establishment is not responsible for obtaining information relating to a deceased donor. This will be carried out by the specialist nurse – organ donation (SN-OD) under NHSBT's licence).

CT2) Donors and organs are characterised before implantation by the collection of information specified in Annex A of The Quality and Safety of Organs Intended for Transplantation: A documentary framework.

CT3) Donors and organs are characterised before implantation by, where considered appropriate, the collection of information specified in Annex B of The Quality and Safety of Organs Intended for Transplantation: A documentary framework.

CT4) All information relating to donor and organ characterisation is kept for a period of 30 years from the date of retrieval of the organ and there is an operating procedure in place to demonstrate how this requirement is complied with.

CT5) Tests required for donor and organ characterisation are carried out by laboratories with United Kingdom Accreditation Service (UKAS) accreditation (to ISO15189:2021).

CT6) Information on organ and donor characterisation reaches the person who will be implanting an organ within a time period that would not compromise the quality and safety of the organ and there is an operating procedure in place to demonstrate how this requirement is complied with.

Retrieval of Organs for transplantation

R1) Procurement is only carried out after all the requirements relating to consent (or authorisation in Scotland) have been met.

R2) Material and equipment used in retrieval meets the requirements of The Medical Devices Regulations 2002 (SI 2002/618) (as amended) (UK MDR 2002), where these apply, and there is an operating procedure in place to demonstrate how this requirement is complied with.

R3) Reusable instruments used in retrieval are subject to a validated cleaning and sterilisation procedure for removal of infectious agents, which is documented.

R4) Endeavours are made to follow-up a living donor for the purposes of identifying and managing any event potentially relating to the quality and safety of the donated organ and any serious adverse reaction in the living donor that may result from the donation

Organ preservation

P1) Material and equipment used in organ preservation meet the requirements of The Medical Devices Regulations 2002 (SI 2002/618) (as amended) (UK MDR 2002), where these apply, and there is an operating procedure in place to demonstrate how this requirement is complied with.

P2) Reusable instruments used in organ preservation are subject to a validated cleaning and

sterilisation procedure for removal of infectious agents, which is documented.

P3) Records of perfusion fluid coming into contact with organs are made on the appropriate HTA A and B forms.

Making arrangements to transport an organ

TP1) The integrity of the organ is maintained during transport and the transport time is suitable to ensure the quality and safety of the organ, and there is an operating procedure in place to demonstrate how this requirement is complied with.

TP2) The organ shipping container is suitable for transport of the specified organ.

TP3) The organ shipping container used for transporting organs from the licensed premises is labelled with the information specified in The Quality and Safety of Organs Intended for Transplantation: A documentary framework, and there is an operating procedure in place to demonstrate how this requirement is complied with.

TP4) Transported organs are accompanied by a report on the organ and donor characterisation, and there is an operating procedure in place to demonstrate how this requirement is complied with.

TP5) Arrangements are in place to ensure that any organisations transporting organs on behalf of the licence holder meet the requirements for transportation and serious adverse event and reaction reporting specified in the framework document.

Implantation

I1) The identification of the donor and the collection of the information in Annex A and B of The Quality and Safety of Organs Intended for transplantation: A documentary framework, are verified prior proceeding to implant an organ, and there is an operating procedure in place to demonstrate how this requirement is complied with.

I2) Compliance with the conditions of preservation and transport outlined in The Quality and Safety of Organs Intended for Transplantation: A documentary framework are verified prior to proceeding to implant an organ.

I3) Where any of the information specified in Annex A of The Quality and Safety of Organs Intended for Transplantation: A documentary framework is not available; a risk-benefit analysis is conducted to determine whether the expected benefits for the recipient of the organ outweigh the risks posed by the lack of any information.

Traceability – *(these criteria apply to all licensed activities)*

TC1) The data required to ensure traceability of organs are recorded using the HTA A and B forms, which are returned to NHSBT within 7 days, and there is an operating procedure in place to demonstrate how this requirement is complied with.

TC2) There is an identification system for donor and recipient to identify each donation and each of the organs and recipients associated with it.

TC3) A record (date and time) of the transportation of organs arriving at and/or leaving the establishment is kept for 30 years as part of the traceability information.

Serious adverse events and adverse reactions (SAEARs) – (these criteria apply to all licensed activities)

S1) Operating procedures are in place for the management of a serious adverse event or a serious adverse reaction.

S2) Serious adverse events and reactions are reported to NHSBT within 24 hours of discovery, a follow-up report is provided within 90 days, and there is an operating procedure in place to demonstrate how this requirement is complied with.

S3) Third parties, such as those undertaking testing or transportation, are instructed to report any serious adverse events and reactions to the licence holder within 24 hours of discovery.

General – (these criteria apply to all licensed activities)

GN1) Healthcare personnel directly involved in the chain from donation to the transplantation or disposal of an organ are competent and suitably qualified or trained to perform their tasks.

GN2) Healthcare personnel directly involved in the chain from donation to the transplantation or disposal of an organ are provided with the training necessary to perform their tasks.

GN3) Medical activities are performed under the advice and guidance of a registered medical practitioner, and there are operating procedures in place to demonstrate this.